Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.

Satoshi IkedaTerufumi KatoHirotsugu KenmotsuTakashi OguraYuki SatoAoi HinoToshiyuki HaradaKaoru KubotaTakaaki TokitoIsamu OkamotoNaoki FuruyaToshihide YokoyamaShinobu HosokawaTae IwasawaRika KasajimaYohei MiyagiToshihiro MisumiHiroaki Okamoto

Published in: The oncologist (2022)

Atezolizumab may be one of the treatment options for patients with NSCLC with comorbid IP, despite the high risk of developing pneumonitis. This clinical trial was retrospectively registered in the Japan Registry of Clinical Trials on August 26, 2019, (registry number: jRCTs031190084, https://jrct.niph.go.jp/en-latest-detail/jRCTs031190084).

Keyphrases

clinical trial
phase ii
open label
double blind
phase iii
small cell lung cancer
randomized controlled trial
advanced non small cell lung cancer
placebo controlled
epidermal growth factor receptor
idiopathic pulmonary fibrosis